[ad_1]
October 24, 2018
Triple negative bad cancer is an aggressive form of bad cancer and has been difficult to treat. Now, oncologists want to take advantage of immunotherapy. At the ESMO Congress, Matteo Lambertini talks about the first promising treatment.
The interview in written form:
Philipp Schuldt: Many doctors have patients with bad cancer, endocrine treatment as obtained with tamoxifen or anastrozole. But what happens if patients still undergo tumor progression under this therapy?
Matteo Lambertini: Fortunately, in the past, we have made a number of important advances in the treatment of women with hormone receptor-positive bad cancer, both early and metastatic. This also applies to patients with tumor progression on standard therapy with tamoxifen and aromatase inhibitors.
In addition to chemotherapy, we now have several different options. According to current guidelines, women with hormone receptor-positive advanced bad cancer should be treated with various endocrine treatments before chemotherapy – unless urgently needed chemotherapy.
New target agents may delay treatment resistance in parallel with endocrine therapy. This means that patients will survive longer under this therapy. These medications already include drugs already in use, such as everolimus, an mTOR inhibitor and CDK4 / 6 inhibitors already used clinically. Some of these agents, presented here at the ESMO conference, will likely be available in the coming years.
Philipp Schuldt: What role does immunotherapy play in bad cancer?
Matteo Lambertini: Immunotherapy is up to now less prevalent in bad cancer than other cancers. We hang a little after. But here at the ESMO Congress, we present the first trial of phase III immunotherapy and randomized chemotherapy in patients with triple negative bad cancer. This study shows some interesting results, such as an improvement in overall survival after 10 months in patients with triple negative bad cancer, PD-L1. We do not see such results so often, especially in this aggressive form of bad cancer.
Philipp Schuldt: Does this mean that immunotherapies are more promising in triple negative bad cancer?
Matteo Lambertini: The data we have collected so far comes from Phase III trials on triple negative bad cancer, but there are already preliminary results from Phase I and Phase 2 studies II in another context, namely HER2. positive bad cancer. However, several studies are underway to test immunotherapy in other subtypes of tumors, including luminal type cancer and HER2 bad cancer.
Philipp Schuldt: Thank you, Mr Lambertini!
ESMO 2018 Congress News
Source link
